Actively Recruiting
Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis
Led by Region Skane · Updated on 2024-07-15
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to study the risk of developing rifampicin resistance in the common bacteria Staphylococcus aureus among people treated for latent tuberculosis infection. It compares two widely used treatment options: a 4-month course of rifampicin and a 6-9 month course of isoniazide. The study also explores whether mutations linked to rifampicin resistance accumulate over time and looks at how resistant bacteria might spread within households. Participants receive treatment as prescribed by their doctors, either rifampicin once daily for 4 months or isoniazide with vitamin B6 once daily for 6 to 9 months. The study itself does not assign treatments but observes people already prescribed these options. Swabs are taken from the nose, throat, groin, and any wounds before, during, and after treatment to test for resistant bacteria and analyze genetic changes. Throughout the study, participants will undergo repeated bacterial cultures and genomic testing to monitor resistance development. Household members of participants with rifampicin-resistant bacteria will also be examined for transmission. The main outcome is tracking the occurrence of rifampicin-resistant Staphylococcus aureus over five months, with additional monitoring of resistance mutations over ten months. The study started in 2021 and will continue until late 2026.
CONDITIONS
Brief Title
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with latent tuberculosis
- Prescribed either 4 months rifampicin or 6-9 months isoniazide
- Provided informed consent
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 to 9 months depending on treatment duration
Participants who undergo routine treatment for latent tuberculosis are observed with swabs taken from the nose, throat, groin, and possible wounds for culture and resistance testing before, during, and after their treatment.
Multiple visits during and after treatment for sample collection
Trial Site Locations
Total: 1 location
1
Skåne University Hospital
Malmö, Sweden, 20502
Actively Recruiting
Research Team
A
Anton Reepalu, PhD
A
Anna Nilsson, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here